NCT05485753View on ClinicalTrials.gov

A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

February 10, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Primary Central Nervous System LymphomaSecondary Central Nervous System Lymphoma
Interventions
DRUG

GNC-038

Administration by intravenous infusion

Trial Locations (4)

100070

Beijing Tiantan Hospital, Capital Medical University, Beijing

Unknown

Beijing GoBroad Boren Hospital, Beijing

Guangdong Provincial People's Hospital, Guangzhou

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
collaborator

SystImmune Inc.

INDUSTRY

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

NCT05485753 - A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) | Biotech Hunter | Biotech Hunter